Adult Dosing

Bacterial conjunctivitis

IQuix

• Days 1 through 3: 1-2 drops in the affected eye(s) q30 min-2 hrs while awake and approximately 4 and 6 hrs after retiring
• Day 4 through 16 (through treatment completion): 1-2 drops in the affected eye(s) q1-4 hrs while awake

Quixin

• Days 1 and 2: 1-2 drops in the affected eye(s) q2 hrs while awake (MAX: 8 times/day)
• Days 3 to 7: 1-2 drops in the affected eye(s) q4 hrs while awake (MAX: 4 times/day)

Pediatric Dosing

Bacterial conjunctivitis

Quixin

• Child > 1 yrs
• Days 1 and 2: 1-2 drops in the affected eye(s) q2 hrs while awake (MAX: 8 times/day)
• Days 3 to 7: 1-2 drops in the affected eye(s) q4 hrs while awake (MAX: 4 times/day)

IQuix

• Child > 6 yrs
• Days 1 through 3: 1-2 drops in the affected eye(s) q30 min-2 hrs while awake and approximately 4 and 6 hrs after retiring
• Day 4 through 16 (through treatment completion): 1-2 drops in the affected eye(s) q1-4 hrs while awake

[Outline]

• Adult Dosing
• Pediatric Dosing

• Indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria:

Gram-positive bacteria

• Corynebacterium species
• Staphylococcus aureus
• Staphylococcus epidermidis
• Streptococcus pneumoniae
• Viridans group streptococci

Gram-negative bacteria

• Pseudomonas aeruginosa
• Serratia marcescens
• Note: Efficacy for Corynebacterium species, Viridans group streptococci, and Serratia marcescens was studied in fewer than 10 infections

• Hx. of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustment

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustment

See Supplemental Patient Information

• Ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye
• Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, even following a single dose
• Prolonged use may result in overgrowth of nonsusceptible organisms
• Discontinue use immediately at the first sign of rash or allergic reaction
• Avoid contaminating the applicator tip with material from the eye, fingers or other source
• While receiving treatment, patients should wear sunglasses and avoid exposure to bright light

Supplemental Patient Information

• Advise patients not to wear contact lenses if they have signs and symptoms of corneal ulcer
• Avoid contaminating the applicator tip with material from the eye, fingers or other source
• Advise patient to discontinue medication immediately and contact physican at the first sign of a rash or allergic reaction
• While receiving treatment, patients should wear sunglasses and avoid exposure to bright light

Iquix, Quixin interacts with :

	Antacids
	Bactrim
	Calcium Polycarbophil
	Carafate
	Didanosine
	FiberCon
	Iron
	Procainamide
	Pronestyl
	Septra
	Sucralfate
	Videx
	Videx EC
	Zinc

Pregnancy Category:C

Breastfeeding: Safety unknown; however minimal systemic absorption. Maternal use of levofloxacin opthalmic presents negligible risk for the nursing infant. This information based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 December 2010).

• CNS: Headache
• GI: Taste disturbance, diarrhea, dyspepsia, nausea
• EENT: Decreased/blurred vision, instillation site irritation/discomfort, ocular infection, photophobia, ocular pain/discomfort, throat irritation
• MISC: Fever, infection, superinfection

• Anti-infective; inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair, and recombination
• Minimal systemic absorption ; CYP450: unknown
• Renally excreted: Urine primarily (87% unchanged)
• Half-life: 6-8 hrs

US Trade Name(s)

• Iquix
• Quixin

US Availability

levofloxacin (generic)

• OPTH SOLN: 0.5 % (5 mL)

Iquix

• OPTH SOLN: 1.5% (5 mL)

Quixin

• OPTH SOLN: 0.5% (5 mL)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Oftaquix

UK Availability

Oftaquix

• OPTH SOLN: 0.5% (5 mL)

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Antimicrobials

Antibiotics

Quinolones

Infectious Disease

Antibiotics

Quinolones

Antimicrobials

Ophthalmic Anti-infectives

Infectious Disease

Ophthalmic Anti-infectives

Ophthalmic

Ophthalmic Anti-infectives